Kazia Therapeutics Limited (NASDAQ:KZIA – Get Free Report)’s stock price fell 3.6% during mid-day trading on Tuesday . The stock traded as low as $0.32 and last traded at $0.32. 238,340 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 4,918,213 shares. The stock had previously closed at $0.33.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and set a $2.00 price objective on shares of Kazia Therapeutics in a report on Friday, July 12th.
Check Out Our Latest Stock Analysis on KZIA
Kazia Therapeutics Price Performance
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Kazia Therapeutics stock. Platinum Investment Management Ltd. acquired a new position in Kazia Therapeutics Limited (NASDAQ:KZIA – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,821,887 shares of the company’s stock, valued at approximately $801,000. Platinum Investment Management Ltd. owned 11.15% of Kazia Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 30.89% of the company’s stock.
Kazia Therapeutics Company Profile
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.
Further Reading
- Five stocks we like better than Kazia Therapeutics
- Ride Out The Recession With These Dividend Kings
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Do ETFs Pay Dividends? What You Need to Know
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.